Table 2

First line anti-tuberculosis drug resistance in new and previously treated patients
Total number of specimens = 2100 Previous anti-TB treatment status
New Previously treated Total
N % (95% CI) N % (95% CI) N % (95% CI)
Total DST results 121 5.8 98 4.7 219 10.4
I Any resistance to H 32 26.4 (19.4–35.4) 46 46.9 (37.1–56.8) 78 35.6 (29.3–42.0)
Any resistance to R 12 9.9 (5.8–16.5) 27 27.6 (18.7–36.4) 39 17.8 (12.7–22.9)
Any resistance to E 18 14.9 (9.6–22.3) 33 33.7 (24.3–43.0) 51 23.3 (17.7–28.9)
Any resistance to S 34 28.1 (20.9–36.7) 34 34.7 (25.3–44.1) 68 31.1 (24.9–37.2)
II Resistance to H only 10 8.3 (4.7–15.3) 14 14.3 (7.1–20.9) 24 10.9 (6.8–15.1)
Resistance to R only 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
Resistance to E only 0 0 (0–0) 7 7.1 (1.9–12.1) 7 3.1 (0.9–5.5)
Resistance to S only 15 12.4 (8.6–21.4) 11 11.2 (4.8–17.2) 26 11.9 (7.6–16.2)
Total mono-resistance 25 20.7 (13.4–27.9) 32 32.6 (23.4–41.9) 57 26.02 (20.2-31.9)
III H + R 1 0.8 (−0.8–2.8) 6 6.1 (1.3–10.7) 7 3.1 (0.9–5.5)
H + R + E 3 2.5 (0.04–6.04) 7 7.1 (1.9–12.1) 10 4.5 (1.8–7.3)
H + R + S 3 2.5 (0.04–6.04) 5 5.1 (0.7–9.3) 8 3.7 (1.2–6.2)
H + R + E + S 5 4.1 (1.1–8.9) 9 9.2 (3.3–14.7) 14 6.4 (3.2–9.6)
Total MDR 12 9.9 (4.6–15.2) 27 27.6 (18.7–36.4) 39 17.8 (12.7–22.9)
IV H + E 4 3.3 (0.5–7.5) 3 3.1 (−0.4–6.4) 7 3.1 (0.9–5.5)
H + S 5 4.1 (1.1–8.9) 2 2.04 (−0.8–4.8) 7 3.1 (0.9–5.5)
H + E + S 1 0.8 (0.8–2.8) 3 3.1 (−0.4–6.4) 4 1.8 (0.1–3.6)
R + E 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
R + S 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
R + E + S 0 0 (0–0) 0 0 (0–0) 0 0 (0–0)
E + S 5 4.1 (1.1–8.9) 4 4.1 (0.12–7.9) 9 4.1 (1.5–6.7)
Total poly-resistance other than MDR 15 12.4 (6.8–18.3) 12 12.2 (5.8–18.7) 27 12.3 (8.0–16.7)

CI – confidence interval, DST – drug susceptibility testing, E – ethambutol, H – isoniazid, R – rifampicin, S – streptomycin.

Sethi et al.

Sethi et al. BMC Infectious Diseases 2013 13:137   doi:10.1186/1471-2334-13-137

Open Data